Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by Daiichi Sankyo Inc.
Information provided by (Responsible Party):
Daiichi Sankyo Inc. Identifier:
First received: June 11, 2013
Last updated: April 27, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2017
  Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)